X4 Pharmaceuticals Stock Market Value
| XFOR Stock | USD 3.71 0.05 1.37% |
| Symbol | XFOR |
Can Biotechnology industry sustain growth momentum? Does XFOR have expansion opportunities? Factors like these will boost the valuation of X4 Pharmaceuticals. Anticipated expansion of XFOR directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating X4 Pharmaceuticals demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (8.92) | Revenue Per Share | Quarterly Revenue Growth 2.152 | Return On Assets | Return On Equity |
Investors evaluate X4 Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating X4 Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause X4 Pharmaceuticals' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between X4 Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if X4 Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, X4 Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
X4 Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to X4 Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of X4 Pharmaceuticals.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in X4 Pharmaceuticals on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding X4 Pharmaceuticals or generate 0.0% return on investment in X4 Pharmaceuticals over 90 days. X4 Pharmaceuticals is related to or competes with Aligos Therapeutics, Karyopharm Therapeutics, Kezar Life, Senti Biosciences, INmune Bio, Skye Bioscience, and OnKure Therapeutics. X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and com... More
X4 Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure X4 Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess X4 Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 23.09 | |||
| Value At Risk | (5.21) | |||
| Potential Upside | 7.57 |
X4 Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for X4 Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as X4 Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use X4 Pharmaceuticals historical prices to predict the future X4 Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0014 | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.27) | |||
| Treynor Ratio | (0.03) |
X4 Pharmaceuticals February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0014 | |||
| Market Risk Adjusted Performance | (0.02) | |||
| Mean Deviation | 3.2 | |||
| Coefficient Of Variation | (10,701) | |||
| Standard Deviation | 4.68 | |||
| Variance | 21.92 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.27) | |||
| Treynor Ratio | (0.03) | |||
| Maximum Drawdown | 23.09 | |||
| Value At Risk | (5.21) | |||
| Potential Upside | 7.57 | |||
| Skewness | 0.8507 | |||
| Kurtosis | 3.5 |
X4 Pharmaceuticals Backtested Returns
Currently, X4 Pharmaceuticals is relatively risky. X4 Pharmaceuticals retains Efficiency (Sharpe Ratio) of 0.0251, which attests that the company had a 0.0251 % return per unit of price deviation over the last 3 months. We have found twenty-three technical indicators for X4 Pharmaceuticals, which you can use to evaluate the volatility of the entity. Please check out X4 Pharmaceuticals' market risk adjusted performance of (0.02), and Information Ratio of (0.02) to validate if the risk estimate we provide is consistent with the expected return of 0.12%. X4 Pharmaceuticals has a performance score of 1 on a scale of 0 to 100. The firm owns a Beta (Systematic Risk) of 1.66, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, X4 Pharmaceuticals will likely underperform. X4 Pharmaceuticals today owns a risk of 4.63%. Please check out X4 Pharmaceuticals treynor ratio, as well as the relationship between the accumulation distribution and price action indicator , to decide if X4 Pharmaceuticals will be following its current price history.
Auto-correlation | -0.06 |
Very weak reverse predictability
X4 Pharmaceuticals has very weak reverse predictability. Overlapping area represents the amount of predictability between X4 Pharmaceuticals time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of X4 Pharmaceuticals price movement. The serial correlation of -0.06 indicates that barely 6.0% of current X4 Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.06 | |
| Spearman Rank Test | -0.41 | |
| Residual Average | 0.0 | |
| Price Variance | 0.05 |
Pair Trading with X4 Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if X4 Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against XFOR Stock
| 0.39 | JUMP | Leveljump Healthcare Corp | PairCorr |
| 0.39 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.33 | ALT | Altimmune | PairCorr |
The ability to find closely correlated positions to X4 Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace X4 Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back X4 Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling X4 Pharmaceuticals to buy it.
The correlation of X4 Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as X4 Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if X4 Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for X4 Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.